Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14811004 | 0.85 | LMNA (0.64) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL30175326 | 0.84 | LMNA (0.75) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL3503653 | 0.84 | LMNA (0.75) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL29425707 | 0.82 | LMNA (1.00) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL322839 | 0.82 | LMNA (1.00) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL3503151 | 0.81 | KMT2A (0.76) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL4119437 | 0.81 | LMNA (0.75) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL31005017 | 0.81 | LMNA (0.75) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL4895762 | 0.81 | LMNA (0.46) | LMNAKMT2AMEN1KDM4ECYP1A2 | |
| SCHEMBL4537862 | 0.80 | KDM5A (0.56) | LMNAKMT2AMEN1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1910171-A | Method for preparation of 6-11 bicyclo erythromycin derivant | ENNATA PHARMACEUTICALS INC (US) | 2007-02-07 | — | — | CN | claimed |
| CN-112574201-B | Arylamine compound, pharmaceutical composition containing arylamine compound, and preparation method and application of arylamine compound | 四川科伦博泰生物医药股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1829870-A1 | 2-(PYRAZOL-1-YL)PYRIDINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-09-05 | — | — | EP | disclosed |
| CN-1910171-A | Method for preparation of 6-11 bicyclo erythromycin derivant | ENNATA PHARMACEUTICALS INC (US) | 2007-02-07 | — | — | CN | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-7135573-B2 | Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine | ENANTA PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-7022679-B2 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060058248-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | XU GUOYOU | 2006-03-16 | — | — | US | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005070918-A1 | PROCESS FOR THE PREPARATION OF T-11 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20040171818-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058248-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | CYP2B6, CYP2D6, CYP2C9 | LMNA 548/4885KMT2A 4090/4885MEN1 4174/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | LMNA 2866/4885KMT2A 2391/4885MEN1 13/4885 |
| US-20040171818-A1 | Processes for the preparation of 6-11 bicyclic erythromycin derivatives | CYP2B6, CYP7A1, CYP2D6 | LMNA 551/4885KMT2A 4213/4885MEN1 3983/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | LMNA 3279/4885KMT2A 3318/4885MEN1 63/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LMNA 1590/4885KMT2A 602/4885MEN1 136/4885 |
| US-20080039452-A1 | Fused Quinoline Derivative and Use Thereof | TACR2, HRH3, HRH2 | LMNA 4027/4885KMT2A 347/4885MEN1 1457/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | LMNA 3279/4885KMT2A 3318/4885MEN1 63/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | LMNA 3279/4885KMT2A 3318/4885MEN1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.